Roche, in collaboration with KlinRisk Inc, has received the CE-mark for the first Artificial Intelligence (AI)-based risk stratification tool to assess progressive decline in kidney function. This allows Roche to introduce the Chronic Kidney Disease (CKD) algorithm panel on its Navify Algorithm Suite to support care across all stages of the CKD care pathway. The panel includes the new Kidney Klinrisk Algorithm—for early risk assessment of adults diagnosed with CKD as well as adults with diabetes or hypertension at elevated risk for kidney function decline–alongside the established CE-marked Kidney KFRE Algorithm for managing later disease stages of CKD.

The new CKD algorithm panel, available on the Navify Algorithm Suite, marks a step in Roche’s strategy to provide digital health solutions for the growing global burden of CKD. This cloud-based platform integrates with existing hospital systems, giving clinicians a single point of access to order and view algorithm results. The panel is available in Europe and the United Kingdom (UK), with a later launch in the United States (US), the Middle East, and Asia.

"The launch of the AI-based Kidney Klinrisk Algorithm as part of our Chronic Kidney Disease algorithm panel, represents a significant advancement in the fight against this often silent, progressive disease. The panel is designed to support physicians to make more informed decisions and manage patients’ kidney function at every stage of the disease. Most importantly, this also includes the possibility to assess adults with diabetes and hypertension, who are at elevated risk for kidney function decline and not yet diagnosed with CKD," said Matt Sause, CEO, Roche Diagnostics.

CKD affects more than 700 million people worldwide, and is broadly recognised as a global public health challenge. With early diagnosis and appropriate treatment, it is possible to delay or prevent kidney function decline, and reduce cardiovascular risk and related healthcare costs.